Genetic variants in IGF-I, IGF-II, IGFBP-3, and adiponectin genes and colon cancer risk in African Americans and Whites

Keku, Temitope O.; Vidal, Adriana C.; Oliver, Shannon D.; Hoyo, Catherine; Hall, Ingrid J.; Omofoye, Oluwaseun A.; McDoom, M. Maya; Worley, Kendra; Galanko, Joseph; Sandler, Robert S.; Millikan, Robert C.

doi:10.1007/s10552-012-9981-2

Cited by 38 publications

(46 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recently published case–control study that included African-American (231 cases and 306 controls) and white (297 cases, 530 controls) patients assessed the relationships between IGF-1 (CA) 19 , IGF-2 Apa1 , IGFBP-3, and APN gene polymorphism and CRC risk 169. In white patients only, those homozygous for the IGF-1 (CA) 19 repeat exhibited an increased CRC risk (OR=1.77, 1.15 to 2.73), while those carrying the IGF-2 Apa1 A-variant exhibited a decreased CRC risk (OR=0.49, 0.28 to 0.88) 169.…”

Section: Resultsmentioning

confidence: 99%

“…In white patients only, those homozygous for the IGF-1 (CA) 19 repeat exhibited an increased CRC risk (OR=1.77, 1.15 to 2.73), while those carrying the IGF-2 Apa1 A-variant exhibited a decreased CRC risk (OR=0.49, 0.28 to 0.88) 169. The investigators also suggested specific variants of IGF-2R might be associated with increased CRC risk (OR=2.2, 0.9 to 5.4), perhaps explained by modulating circulating levels of IGF-2 170…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Obesity and colorectal cancer

Bardou

Barkun

Martel

2013

Gut

662

479

View full text Add to dashboard Cite

Excess body weight, as defined by the body mass index (BMI), has been associated with several diseases and includes subjects who are overweight (BMI ≥ 25-29.9 kg/m(2)) or obese (BMI ≥ 30 kg/m(2)). Overweight and obesity constitute the fifth leading risk for overall mortality, accounting for at least 2.8 million adult deaths each year. In addition around 11% of colorectal cancer (CRC) cases have been attributed to overweight and obesity in Europe. Epidemiological data suggest that obesity is associated with a 30-70% increased risk of colon cancer in men, whereas the association is less consistent in women. Similar trends exist for colorectal adenoma, although the risk appears lower. Visceral fat, or abdominal obesity, seems to be of greater concern than subcutaneous fat obesity, and any 1 kg/m(2) increase in BMI confers additional risk (HR 1.03). Obesity might be associated with worse cancer outcomes, such as recurrence of the primary cancer or mortality. Several factors, including reduced sensitivity to antiangiogenic-therapeutic regimens, might explain these differences. Except for wound infection, obesity has no significant impact on surgical procedures. The underlying mechanisms linking obesity to CRC are still a matter of debate, but metabolic syndrome, insulin resistance and modifications in levels of adipocytokines seem to be of great importance. Other biological factors such as the gut microbiota or bile acids are emerging. Many questions still remain unanswered: should preventive strategies specifically target obese patients? Is the risk of cancer great enough to propose prophylactic bariatric surgery in certain patients with obesity?

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Obesity and colorectal cancer

Bardou

Barkun

Martel

2013

Gut

662

479

View full text Add to dashboard Cite

show abstract

“…Several genetic polymorphisms in the IGFBP-3 gene have been identified for predicting the development, progression, and clinical outcomes of colorectal cancer, but A-202C and C2133G were the most common ones (Poole et al, 2012). Many previous genetic studies have suggested that IGFBP A-202C and C2133G polymorphisms play an important role in colorectal carcinogenesis (Le Marchand et al, 2005;Morimoto et al, 2005;Samowitz et al, 2006;Slattery et al, 2006;Xiang et al, 2009;Feik et al, 2010;Keku et al, 2012;Ollberding et al, 2012), while other studies found no convincing evidence of these polymorphisms in increasing the risk of colorectal cancer (Slattery et al, 2004;Wong et al, 2005;Pechlivanis et al, 2007). This controversy could be explained with several reasons, including the differences in study design, sample size, ethnicity, and statistical method.…”

Section: Discussionmentioning

confidence: 99%

“…Of these articles, 66 were excluded after reviewing their titles and key words; then, abstract and full text were reviewed, and another 68 papers were excluded. Eleven case-control studies met our inclusion criteria (Le Marchand et al, 2005;Morimoto et al, 2005;Wong et al, 2005;Samowitz et al, 2006;Slattery et al, 2004Slattery et al, , 2006Pechlivanis et al, 2007;Xiang et al, 2009;Feik et al, 2010;Keku et al, 2012;Ollberding et al, 2012). The publication years of the involved studies ranged from 2004 to 2012.…”

Section: Baseline Characteristics Of Included Studiesmentioning

confidence: 99%

IGFBP-3 A-202C and C2133G polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Recent evidence suggests that genetic variations in the IGFBP-3 gene may impact susceptibility to colorectal cancer, but individually published results are inconclusive. Our meta-analysis was aimed at providing a more precise estimation of these associations. An extensive literature search was conducted for appropriate articles published before May 1, 2013. This meta-analysis was performed using the STATA 12.0 software. The crude odds ratios (OR) with 95% confidence interval (CI) were calculated. Eleven case-control studies were included with a total of 11,895 colorectal cancer patients and 17,147 healthy controls. Our meta-analysis indicated that the G variant of IGFBP-3 C2133G polymorphism may be associated with increased colorectal cancer risk. However, no statistically significant association was noted between IGFBP-3 A-202C polymorphism and colorectal cancer risk. No publication bias was detected in this metaanalysis. The current meta-analysis suggests that the IGFBP-3 C2133G polymorphism may confer susceptibility to colorectal cancer. The G IGFBP-3 A-202C and C2133G in colorectal cancer risk variant of the IGFBP-3 C2133G polymorphism may serve as a useful biomarker for predicting the risk of colorectal cancer.

show abstract

“…Partida-Perez et al, 2010;He et al, 2011;Liu et al, 2011;Keku et al, 2012;Tsilidis et al, 2009;Wang et al, 2009), respectively…”

unclassified

Five Common Haplotype-Tagging Variants of Adiponectin (ADIPOQ) and Cancer Susceptibility: A Meta-Analysis

Sang

et al. 2014

Genetic Testing and Molecular Biomarkers

View full text Add to dashboard Cite

show abstract

Genetic variants in IGF-I, IGF-II, IGFBP-3, and adiponectin genes and colon cancer risk in African Americans and Whites

Cited by 38 publications

References 79 publications

Obesity and colorectal cancer

Obesity and colorectal cancer

IGFBP-3 A-202C and C2133G polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies

Five Common Haplotype-Tagging Variants of Adiponectin (ADIPOQ) and Cancer Susceptibility: A Meta-Analysis

Contact Info

Product

Resources

About